Clinical Trial End Points in ADPKD

June 6, 2019 // 0 Comments

Despite our current understanding regarding the pathophysiology of autosomal dominant polycystic kidney disease (ADPKD), only one therapy has been approved by the US FDA. There has been recent interest in redefining end points for clinical trials [read more...]

Kidney CRISPR: How Close Are We?

August 10, 2018 // 0 Comments

CRISPR (clustered regularly interspaced short palindromic repeats) gene editing is making huge waves in biomedical research. In fact, the lay press is devoting significant coverage to CRISPR as well. See this interesting piece on CRISPR from 60 [read more...]